A vaccine to help prevent MenB in adolescents and young adults

TRUMENBA is a vaccine to help prevent MenB (invasive meningococcal disease [IMD] caused by N. meningitidis serogroup B bacteria), for use in individuals aged 10 through 25 years. 

Even if you have, or your child has, already been vaccinated against meningococcal meningitis,

 the vaccines may not have included serogroup B – the most common serogroup associated with IMD in Canada. 

How does it work?

TRUMENBA targets a protein found in over 95% of bacteria that cause meningitis B. It works by helping the body make antibodies (the body’s natural defenses), which can help protect individuals against this disease. These antibodies kill the bacteria that cause meningitis B.
If a vaccinated person comes into contact with the bacteria that cause this disease, their body is usually ready to destroy them. 

How is it given?

Your healthcare professional will inject TRUMENBA into the upper arm muscle as a single injection of 0.5 mL, on two or three separate occasions.

2-dose schedule
3-dose schedule
Your doctor will choose your dosing schedule according to your or your child's risk of MenB disease.
A booster dose may be considered depending on your or your child’s risk of invasive meningococcal disease.

NACI recommendation: 

NACI recommends that TRUMENBA may be considered as an option for individuals 10–25 years of age who are not at higher risk of meningococcal disease than the general population, in a 2-dose schedule (0 and 6 months), to reduce the risk of invasive serogroup B meningococcal disease.

NACI: National Advisory Committee on Immunization.

A vaccine for meningitis B prevention.

Thank you for signing up for your TRUMENBA vaccine reminder!